These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12917511)

  • 21. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.
    Barlow LJ; McKiernan JM; Benson MC
    J Urol; 2013 Mar; 189(3):834-9. PubMed ID: 23123371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guérin for superficial bladder cancer recurrence.
    Irie A; Uchida T; Yamashita H; Matsumoto K; Satoh T; Koh H; Shimura S; Iwamura M; Baba S
    Int J Urol; 2003 Apr; 10(4):183-9. PubMed ID: 12657096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravesical bacillus Calmette-Guerin (BCG) instillation for primary and recurring T1G3 bladder cancers.
    Okamura T; Akita H; Ando R; Kawai Y; Tozawa K; Kohri K
    Asian Pac J Cancer Prev; 2010; 11(4):1107-10. PubMed ID: 21133632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials.
    Sylvester RJ; van der Meijden AP; Witjes JA; Kurth K
    J Urol; 2005 Jul; 174(1):86-91; discussion 91-2. PubMed ID: 15947584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravesical bacillus Calmette-Guérin efficiently reduces p70S6K1 but not 4E-BP1 phosphorylation in nonmuscle invasive bladder cancer.
    Ferrari KL; de Camargo JA; Rocha GZ; Carvalheira JB; Saad MJ; Billis A; Reis LO
    J Urol; 2015 Feb; 193(2):682-9. PubMed ID: 25200808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
    J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Classification, favorable characteristics, prevention and treatment of adverse side-effects associated with Bacillus Calmette-Guerin in the treatment of superficial bladder cancer].
    Saint F; Salomon L; Quintela R; Cicco A; Abbou CC; Chopin DK
    Ann Urol (Paris); 2002 Mar; 36(2):120-31. PubMed ID: 11969046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group.
    Witjes JA; v d Meijden AP; Collette L; Sylvester R; Debruyne FM; van Aubel A; Witjes WP
    Urology; 1998 Sep; 52(3):403-10. PubMed ID: 9730451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria.
    Herr HW
    J Urol; 2012 Feb; 187(2):435-7. PubMed ID: 22177154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravesical treatment of severe bacillus Calmette-Guerin cystitis.
    Palou J; Rodríguez-Villamil L; Andreu-Crespo A; Salvador-Bayarri J; Vicente-Rodríguez J
    Int Urol Nephrol; 2001; 33(3):485-9. PubMed ID: 12230277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group.
    Koga H; Ozono S; Tsushima T; Tomita K; Horiguchi Y; Usami M; Hirao Y; Akaza H; Naito S;
    Int J Urol; 2010 Sep; 17(9):759-66. PubMed ID: 20604814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer.
    Brake M; Loertzer H; Horsch R; Keller H
    Urology; 2000 May; 55(5):673-8. PubMed ID: 10792077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials.
    Han RF; Pan JG
    Urology; 2006 Jun; 67(6):1216-23. PubMed ID: 16765182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
    Yi SH; Ye G; Wang XW; Jin HS; Zhang YN; Yan ZL
    Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravesical Bacillus Calmette-Guerin for treating bladder cancer.
    Boyd LA
    Urol Nurs; 2003 Jun; 23(3):189-91, 199; quiz 192. PubMed ID: 12861735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term results of intravesical bacillus Calmette-Guérin therapy for stage T1 superficial bladder cancer.
    Droller MJ
    J Urol; 2001 Feb; 165(2):701-2. PubMed ID: 11233047
    [No Abstract]   [Full Text] [Related]  

  • 38. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial.
    Martínez-Piñeiro JA; Martínez-Piñeiro L; Solsona E; Rodríguez RH; Gómez JM; Martín MG; Molina JR; Collado AG; Flores N; Isorna S; Pertusa C; Rabadán M; Astobieta A; Camacho JE; Arribas S; Madero R;
    J Urol; 2005 Oct; 174(4 Pt 1):1242-7. PubMed ID: 16145378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation.
    Takayama H; Nishimura K; Tsujimura A; Nakai Y; Nakayama M; Aozasa K; Okuyama A; Nonomura N
    J Urol; 2009 Apr; 181(4):1894-900. PubMed ID: 19237175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma.
    Kaasinen E; Rintala E; Pere AK; Kallio J; Puolakka VM; Liukkonen T; Tuhkanen K
    J Urol; 2000 Jul; 164(1):47-52. PubMed ID: 10840422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.